[1]
|
B. Marcet and J. M. Boeynaems, “Relationships between Cystic Fibrosis Transmembrane Conductance Regulator, Extracellular Nucleotides and Cystic Fibrosis,” Pharmacology & Therapeutics, Vol. 112, No. 3, 2006, pp. 719- 732. doi:10.1016/j.pharmthera.2006.05.010
|
[2]
|
M. T. Clunes and R. C. Boucher, “Front-Runners for Pharmacotherapeutic Correction of the Airway Ion Transport Defect in Cystic Fibrosis,” Current Opinion in Pharmacology, Vol. 8, No. 3, 2008, pp. 292-299.
doi:10.1016/j.coph.2008.04.006
|
[3]
|
P. T. Bye and M. R. Elkins, “Other Mucoactive Agents for Cystic Fibrosis,” Paediatric Respiratory Reviews, Vol. 8, No. 1, 2007, pp. 30-39. doi:10.1016/j.prrv.2007.02.008
|
[4]
|
D. Kellerman, et al., “Inhaled P2Y2 Receptor Agonists as a Treatment for Patients with Cystic Fibrosis Lung Disease,” Advanced Drug Delivery Reviews, Vol. 54, No. 11, 2002, pp. 1463-1474.
doi:10.1016/S0169-409X(02)00154-0
|
[5]
|
B. R. Yerxa, et al., “Potency and Duration of Action of Synthetic P2Y2 Receptor Agonists on Schirmer Scores in Rabbits,” Advances in Experimental Medicine and Biology, Vol. 506, 2002, pp. 261-265.
|
[6]
|
D. Kellerman, et al., “Denufosol: A Review of Studies with Inhaled P2Y(2) Agonists that Led to Phase 3,” Pulmonary Pharmacology & Therapeutics, Vol. 21, No. 4, 2008, pp. 600-607. doi:10.1016/j.pupt.2007.12.003
|
[7]
|
M. R. Knowles, et al., “Extracellular ATP and UTP Induce Chloride Secretion in Nasal Epithelia of Cystic Fibrosis Patients and Normal Subjects in Vivo,” Chest, Vol. 101, No. 3, 1992, pp. 60-63.
doi:10.1378/chest.101.3_Supplement.60S
|
[8]
|
M. R. Knowles, et al., “Pharmacological Treatment of Abnormal Ion Transport in the Airway Epithelium in Cystic Fibrosis,” Chest, Vol. 107, No. 2, 1995, pp. 71-76.
doi:10.1378/chest.107.2_Supplement.71S
|
[9]
|
S. Yamamoto, et al., “Regulation of Extracellular UTP- Activated Cl? Current by P2Y-PLC-PKC Signaling and ATP Hydrolysis in Mouse Ventricular Myocytes,” The Journal of Physiology, Vol. 57, No. 2, 2007, pp. 85-94.
doi:10.2170/physiolsci.RP011406
|
[10]
|
B. R. Yerxa, et al., “Pharmacology of INS37217 [P(1)- (Uridine 5')-P(4)-(2'-deoxycytidine 5')tetraphosphate, Tetrasodium Salt], a Next-Generation P2Y(2) Receptor Agonist for the Treatment of Cystic Fibrosis,” Journal of Pharmacology and Experimental Therapeutics, Vol. 302, No. 3, 2002, pp. 871-880. doi:10.1124/jpet.102.035485
|
[11]
|
R. R. Deterding, et al., “Phase 2 Randomized Safety and Efficacy Trial of Nebulized Denufosol Tetrasodium in Cystic Fibrosis,” American Journal of Respiratory and Critical Care Medicine, Vol. 176, No. 4, 2007, pp. 362- 369. doi:10.1164/rccm.200608-1238OC
|
[12]
|
S. Storey and G. Wald, “Novel Agents in Cystic Fibrosis,” Nature Reviews Drug Discovery, Vol. 7, 2008, pp. 555-556. doi:10.1038/nrd2603
|
[13]
|
F. Ratjen, “New Pulmonary Therapies for Cystic Fibrosis,” Current Opinion in Pulmonary Medicine, Vol. 13, No. 6, 2007, pp. 541-546.
doi:10.1097/MCP.0b013e3282efbc56
|
[14]
|
R. Schreiber and K. Kunzelmann, “Purinergic P2Y6 Receptors Induce Ca2+ and CFTR Dependent Cl? Secretion in Mouse Trachea,” Cell Physiol Biochem, Vol. 16, 2005, pp. 99-108. doi:10.1159/000087736
|
[15]
|
M. Taira, et al., “Adenosine A3 Receptor-Mediated Potention of Mucociliary Transport and Epithelial Ciliary Motility,” American Journal of Physiology—Lung Cellular and Molecular Physiology, Vol. 282, 2002, pp. 556- 562.
|
[16]
|
S. T. Ballard, et al., “Liquid Secretion Inhibitors Reduce Mucociliary Transport in Glandular Airways,” American Journal of Physiology—Lung Cellular and Molecular Physiology, Vol. 283, 2002, pp. 329-335.
|
[17]
|
T. Ma, et al., “Thiazolidinone CFTR Inhibitor Identified by High-Throughput Screening Blocks Cholera Toxin- Induced Intestinal Fluid Secretion,” Journal of Clinical Investigation, Vol. 110, 2002, pp. 1651-1658.
|
[18]
|
J. R. Thiagarajah, et al., “Prevention of Toxin-Induced Intestinal Ion and Fluid Secretion by a Small-Molecule CFTR Inhibitor,” Gastroenterology, Vol. 123, No. 2, 2004, pp. 511-519. doi:10.1053/j.gastro.2003.11.005
|
[19]
|
A. Perez, et al., “CFTR Inhibition Mimics the Cystic Fibrosis Inflammatory Profile,” American Journal of Physiology—Lung Cellular and Molecular Physiology, Vol. 292, No. 2, 2006, pp. 383-395.
doi:10.1152/ajplung.00403.2005
|
[20]
|
B. R. Grubb, et al., “Mucociliary Transport Determined by in Vivo Microdialysis In the Airways of Normal and CF Mice,” American Journal of Physiology—Lung Cellular and Molecular Physiology, Vol. 286, No. 3, 2004, pp. 588-595. doi:10.1152/ajplung.00302.2003
|
[21]
|
N. Wienk?tter, et al., “The Effect of Thyme Extract on Beta2-Receptors and Mucociliary Clearance,” Planta Medica, Vol. 73, No. 7, 2007, pp. 629-635.
doi:10.1055/s-2007-981535
|
[22]
|
F. Begrow, et al., “Effect of Myrtol Standardized and Other Substances on the Respiratory Tract: Ciliary Beat Frequency and Mucociliary Clearance as Parameters,” Advances in Therapy, Vol. 29, No. 4, 2012, pp. 350-358.
doi:10.1007/s12325-012-0014-z
|
[23]
|
A. T. Kimoto, et al., “A New, Simple Method of Measuring Mucociliary Clearance in Guinea—Pigs,” Pulmonary Pharmacology & Therapeutics, Vol. 12, No. 1, 1999, pp. 49-54. doi:10.1006/pupt.1999.0169
|
[24]
|
H. Engler and I. Szelenyi, “Tracheal Phenol Red Secretion, a New Method for Screening Mucosecretolytic Compounds,” Journal of Pharmacological Methods, Vol. 11, No. 3, 1984, pp. 151-157.
doi:10.1016/0160-5402(84)90033-0
|
[25]
|
W. H. Colledge, et al., “Generation and Characterization of a DeltaF508 Cystic Fibrosis Mouse Model,” Nature Genetics, Vol. 10, 1995, pp. 445-452.
doi:10.1038/ng0895-445
|
[26]
|
J. N. Snouwaert, et al., “An Animal Model for Cystic Fibrosis Made by Gene Targeting,” Science, Vol. 257, No. 5073, 1992, pp. 1083-1088.
doi:10.1126/science.257.5073.1083
|
[27]
|
K. A. Becker, et al., “Zystische Fibrose—Pathophysiologische Konzepte,” Biospektrum, Vol. 15, 2009, pp. 383- 385.
|
[28]
|
M. Mall, et al., “Increased Airway Epithelial Na+ Absorption Produces Cystic Fibrosis-Like Lung Disease in Mice,” Nature Medicine, Vol. 10, 2004, pp. 487-493.
doi:10.1038/nm1028
|
[29]
|
G. Adam, et al., “Increase in Intracellular Cl? Concentration by cAMP- and Ca2+-Dependent Stimulation of M1 Collecting Duct Cells,” Pflugers Archiv, Vol. 449, No. 5, 2005, pp. 470-478. doi:10.1007/s00424-004-1356-4
|
[30]
|
Z. Cai, et al., “Inhibition of Heterologously Expressed Cystic Fibrosis Transmembane Conductance Regulator Cl? Channels by Non-Sulphonylurea Hypoglycaemic Agents,” British Journal of Pharmacology, Vol. 128, No. 1, 1999, pp. 108-118. doi:10.1038/sj.bjp.0702748
|
[31]
|
P. C. Zamecnik, et al., “Analogues of Diadenosine 5’,5’’’-P1,P4-Tetraphosphate (AP4A) as Potential Anti- Platelet-Aggregation Agents,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, No. 6, 1992, pp. 2370-2373.
doi:10.1073/pnas.89.6.2370
|
[32]
|
E. J. Verspohl and B. Johannwille, “Diadenosine Polyphosphates in Insulin Secreting Cells: Their Interaction with Specific Receptors and Their Degradation,” Diabetes, Vol. 47, No. 11, 1998, pp. 1727-1734.
doi:10.2337/diabetes.47.11.1727
|
[33]
|
S. A. Felicetti, et al., “Comparison of Tracheal Mucous Transport in Rats, Guinea Pigs, Rabbits, and Dogs,” Journal of Applied Physiology, Vol. 51, No. 6, 1981, pp. 1612-1617.
|